Home 
Bratislava Medical Journal 2021 Bratislava Medical Journal Vol.122, No.5, p.305–309,2021
Bratislava Medical Journal 2021 Bratislava Medical Journal Vol.122, No.5, p.305–309,2021
Journal info
|
||||
Select Journal
Journals
Bratislava Medical Journal 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 Ekologia - Ecology Endocrine Regulations General Physiology and Biophysics Neoplasma Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudba 2025Webshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Bratislava Medical Journal Vol.122, No.5, p.305–309,2021 |
||
| Title: Metformin therapy and risk of cancer in patients after heart transplantation | ||
| Author: H. Bedanova, V. Horvath, J. Ondrasek, J. Krejci, P. Dobsak, P. Nemec | ||
| Abstract: BACKGROUND: Diabetes mellitus (DM) and malignancy are recognized among the most common complications increasing mortality in patients after heart transplantation (HTx). Clinical trials have shown a higher risk for different types of tumours in diabetic patients. This risk is potentiated by immunosuppressive therapy in transplant patients. Biguanide metformin has been shown to exhibit anti-tumour activity and we tried to find out whether this effect is valid for heart transplant patients. METHODS: We retrospectively analysed a group of 497 patients, who undergone HTx in our centre between 1998 and 2019. The primary outcome was any malignancy during the 15-year follow-up period and patient’s survival. RESULTS: Out of the 497 patients enrolled in the study, 279 (56 %) had diabetes and 52 (19 %) were treated with metformin. Fifteen-year survival in treated patients without malignancy was 93 %, the remainder for the DM patients was 56 %, with survival in non-DM patients being 74 %. Untreated diabetic patients had 4.7 times higher chance of malignancy than those on metformin (p = 0.01). Fifteen-year survival in metformin treated patients was 53 %, in other DM patients 44 %, and in non-DM patients 51 %. CONCLUSION: Our study showed a significantly lower incidence of malignancies in metformin-treated patients and slightly better overall survival (Tab. 2, Fig. 3, Ref. 19) |
||
| Keywords: biguanide, heart graft, malignancy, diabetes mellitus, survival | ||
| Published online: 13-Apr-2021 | ||
| Year: 2021, Volume: 122, Issue: 5 | Page From: 305, Page To: 309 | |
| doi:10.4149/BLL_2021_051 |
||
|
|
 download file |
|